Biopharmaceutical company Incyte (Nasdaq:INCY) said on Tuesday that the US Food and Drug Administration (FDA) has awarded its Priority Review to the New Drug Application (NDA) for capmatinib as the treatment for first-line and previously treated patients with locally advanced or metastatic MET exon 14 skipping (METex14) mutated non-small cell lung cancer (NSCLC).
Upon US FDA approval, the company's capmatinib will be the first therapy to specifically target METex14 mutated advanced lung cancer, a type of lung cancer with a particularly poor prognosis.
There are no approved therapies that target METex14 mutated advanced NSCLC, which accounts for 85% of lung cancer diagnoses.
Capmatinib (INC280) is reportedly an investigational, oral and selective MET inhibitor discovered by Incyte and licensed to Novartis. METex14 mutations occur in 3-4% of newly-diagnosed advanced NSCLC cases and is a recognized oncogenic driver.
The NDA submission for capmatinib was supported by results from the Novartis-sponsored GEOMETRY mono-1 Phase 2 study, which demonstrated overall response rates of 67.9% and 40.6% among treatment-naïve and previously treated patients, respectively, based on BIRC assessment per RECIST. The study demonstrated that capmatinib provided durable responses among all patients.
All results were based on independent assessment by the BIRC (the Blinded Independent Review Committee) and all tumor CT scans were evaluated in parallel by two radiologists to confirm the response, concluded the company.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML